Who
Alexander Cumbo
Director
Company insider
Files Form 4 as: Director, Stoke Therapeutics; Director, Vor Biopharma; Director, Climb Bio; President and CEO, Solid Biosciences; Director, Verve Therapeutics; Director, Ra Pharmaceuticals; EVP, Chief Commercial Officer, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 118
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $14.3M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 10 Mar 2017
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,674 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,674 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,345 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,345 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $97K16,644 at $5.82 | filing |
| 18 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $97K16,644 at $5.82 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —30,031 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,031 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,031 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —30,031 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $315K48,913 at $6.44 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $315K48,913 at $6.44 | filing |
| 2 Feb 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $517K80,258 at $6.44 | filing |
| 2 Feb 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $517K80,258 at $6.44 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —100,400 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,400 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,400 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —100,400 | filing |
News
Solid Biosciences (NASDAQ:SLDB) Upgraded at UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences (NASDAQ:SLDB) Stock Lifted to Strong-Buy by UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences Inc. (NASDAQ:SLDB) Stock Has Average Price Target of $18.69SLDB · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Alexander Cumbo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.